Beyond ultrapure hemodialysis: A necessary and achievable goal

Hemodialysis International

Volumn 11, Issue SUPPL. 1, 2007, Pages

  Kjellstrand, Carl M ^a,b,c,f   Kjellstrand, Per ^d,e  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e Gambro AB   (Sweden)

^f NONE   (United States)

Author keywords

Dialysis systems; Hemodialysis; Ultrapure

Indexed keywords

C REACTIVE PROTEIN; DIALYSIS FLUID; ENDOTOXIN; ERYTHROPOIETIN; METAL; PEPTIDOGLYCAN; PHTHALIC ACID; PLASTICIZER;

AMYLOIDOSIS; ARTICLE; BACTERIUM CONTAMINATION; BIOCOMPATIBILITY; CANCER; CARDIOVASCULAR SYSTEM; CARPAL TUNNEL SYNDROME; CHRONIC INFLAMMATION; COLONY FORMING UNIT; DIALYSATE; DIALYSIS MEMBRANE; DISEASE SEVERITY; EXTRACORPOREAL CIRCULATION; FILTER; HEART DEATH; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INCREASED APPETITE; INFECTION; MACHINE; METABOLITE; NUTRITION; STANDARD; SURVIVAL; WELLBEING;

EID: 34047093842     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2007.00145.x     Document Type: Article

References (72)

1. U.S. Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005.
2. Kjellstrand C, Buoncristiani U, Ting G, et al. Survival in 415 patients treated by short daily hemodialysis for 948 patient years rivals renal transplant survival [abstract]. Hemodial Int. 2006; 10:118.
3. Canaud B. Lecture at the Annual Dialysis Conference, February 2004, San Antonio, Texas, U.S.A., 2004.
4. Ledebo I. Ultrapure dialysis fluid: Improving conventional and daily dialysis. Hemodial Int. 2004; 8:159-166.
5. Qureshi AR, Alvestrand A, Divino-Filho JC, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 2002; 13(Suppl 1):S28-S36.
6. Tsuchida K, Takemoto Y, Yamagami S, et al. Detection of peptidoglycan and endotoxin in dialysate, using silkworm larvae plasma and limulus amebocyte lysate methods. Nephron. 1997; 75:438-443.
7. Schindler R, Beck W, Deppisch R, et al. Short bacterial DNA fragments: Detection in dialysate and induction of cytokines. J Am Soc Nephrol. 2004; 15:3207-3214.
8. Savey A, Simon F, Izopet J, Lepoutre A, Fabry J, Desenclos JC. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol. 2005; 6:752-760.
9. Kjellstrand CM, Alfrey AC, Eaton JW, et al. Toxicity of materials and medications used in dialysis. Trans Am Soc Artif Intern Organs. 1978; 24:764-769.
10. Kambia K, Dine T, Azar R, Gresisser B, Luyckx M, Brunet C. Comparative study of the leachability of DEHP and of trioctyl trimetallite (TOTM) from hemodialysis tubing. Int J Pharm. 2001; 229:139-136.
11. Kambia K, Gresisser B, Dine T, Dupin-Spriet T, Luyckx M, Brunet C. Evaluation of direct cytotoxicity of trioctyltrimellitate (TOTM), DHEP on hepatocytes. Int J Artif Organs. 2004; 27:971-978.
12. Tickner JA, Schettler T, Guidotti T, McCally M, Rossi M. Health risks posed by use of Di-2-ethylhexyl phthalate (DEHP) in PVC medical devices: A critical review. Am J Int Med. 2001; 39:100-111.
13. Ash SR. The importance of polyvinyl chloride in medical devices and the physician's role in the choice of materials. ASAIO J. 2003; 49:233-236.
14. Yakubovich M, Vienken J. Is there a need for plasticizer-free biomaterials in dialysis therapy? Med Device Technol. 2000; 11:12-3, 18-21.
15. Mettang T, Thomas S, Kiefer T, et al. Uraemic pruritus and exposure to di(2-ethylhexyl) phthalate (DEHP) in haemodialysis patients. Nephrol Dial Transplant. 1996; 11:2439-2443.
16. Mettang T, Fischer FP, Dunst R, Kuhlmann U, Rettenmeier AW. Plasticizers in renal failure: Aspects of metabolism and toxicity. Perit Dial Int. 1997; 17(Suppl 2):S31-S36.
17. Akingbemi BT, Ge R, Klinefelter GR, Zirkin BR, Hardy MP. Phthalate-induced Leydig cell hyperplasia is associated with multiple endocrine disturbances. Proc Natl Acad Sci USA. 2004; 101:775-780.
18. Yamasaki H, Nagake Y, Makino H. Determinations of bisphenol A in effluents of hemodialyzers. Nephron. 2001; 88:376-378.
19. Haishima Y, Hayashi Y, Yagami T, Nakamura T. Elution of bisphenol-A from hemodialyzers consisting of polycarbonate and polysulfone resins. J Biomed Mater Res. 2001; 58:209-215.
20. Hayashi Y, Matsuda R, Haishima Y, Yagami T, Nakamura A. Validation of HPLC and GC-MS systems for bisphenol-A leached from hemodialyzers on the basis of FUMI theory. J Pharm Biomed Anal. 2002; 28:421-429.
21. Sugimura K, Naganuma T, Kakiya Y, Okada C, Sugimura T, Kishimoto T. Endocrine-disrupting chemicals in CAPD dialysate and effluent. Blood Purif. 2001; 19:21-23.
22. Singleton DW, Feng Y, Chen Y, et al. Bisphenol-A and estradiol exert novel gene regulation in human MCF-7 derived breast cancer cells. Mol Cell Endocrinol. 2004; 221:47-55.
23. Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS. Increased incidence of malignancy during chronic renal failure. Lancet. 1975; 1:883-886.
24. Daugirdas JT, Ing TS. First-use reactions during hemodialysis: A definition of subtypes. Kidney Int. 1998; 24(Suppl): S37-S43.
25. Kjellstrand C. The search for scientific truth versus corporate interests. Semin Dial. 1993; 6:281-283.
26. Clemedson C, Barile FA, ChesnéC, et al. MEIC evaluation of acute systemic toxicity: Part VII. Prediction of human toxicity by results from testing the first 30 reference chemicals with 27 further in vitro assays. Part VIII. Multivariate partial least squares evaluation, including the selection of a battery of cell line tests with good prediction of human acute lethal peak blood concentrations for 50 chemicals. ATLA. 2000; 28:161-200.
27. Bosch X. Baxter withdraws dialyzer after 12 patients die. BMJ. 2001; 323:529.
28. Kjellstrand P, Erixon M, Wieslander A, Lindén T, Martinson E. Temperature: The single most important factor for degradation of glucose fluids during storage. Perit Dial Int. 2004; 24:385-391.
29. Linden T, Cohen A, Deppisch R, Kjellstrand P, Wieslander A. 3,4-Dideoxyglucosone-3-ene (3,4-DGE): A cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int. 2002; 62:697-703.
30. Martinson E, Wieslander A, Kjellstrand PT, Boberg U. Toxicity of heat sterilized peritoneal dialysis fluids is derived from degradation of glucose. ASAIO J. 1992; 38:M370-M372.
31. Erixon M, Wieslander A, Linden T, et al. Take care in how you store your PD fluids: Actual temperature determines the balance between reactive and non-reactive GDPs. Perit Dial Int. 2005; 25:583-590.
32. Wieslander A, Nordin MK, Kjellstrand PT, Boberg U. Toxicity of peritoneal dialysis fluids on cultured fibroblasts L-929. Kidney Int. 1991; 40:77-79.
33. Kjellstrand PT, Lilliehorn G, Rydhög G. Toxicity testing of polymer materials for dialysis equipment: Is there any need for in vivo testing. Cell Biol Toxicol. 1994; 10:137-142.
34. Kjellstrand P, Lindqvist E, Nilsson-Thorell K. Toxicity testing of polymer materials for dialysis equipment: Reconsidering in vivo testing. ATLA. 2000; 28: 495-502.
35. Leong AS, Disney AP, Gove DW. Spallation and migration of silicone from blood-pump tubing in patients on hemodialysis. N Engl J Med. 1982; 306:135-140.
36. Altmann P, Dodd S, Williams A, Marsh F, Cunningham J. Silicone-induced hypercalcaemia in haemodialysis patients. Nephrol Dial Transplant. 1987; 2:26-29.
37. Vanholder R. Biocompatibility issues in hemodialysis. Clin Mater. 1992; 10:87-133.
38. Laohapand T, Osman EM, Morley AR, Ward MK, Kerr DN. Accumulation of silicone elastomer in regular dialysis. Proc Eur Dial Transplant Assoc. 1983; 19:143-152.
39. Bommer J, Ritz E. Spallation of dialysis materials - problems and perspectives. Nephron. 1985; 39:285-289.
40. Barron D, Harbottle S, Hoenich NA, Morley AR, Appleton D, McCabe JF. Particle spallation induced by blood pumps in hemodialysis tubing sets. Artif Organs. 1986; 10: 226-235.
41. Ward RA. Dialysis water as a determinant of the adequacy of dialysis. Semin Nephrol. 2005; 25:102-111.
42. Ledebo I, Nystrand R. Defining the microbiological quality of dialysis fluid. Artif Organs. 1999; 23:37-43.
43. Schoots AC, Mikkers FE, Claessens HA, De Smet R, Van Landschoot N, Ringoir SM. Characterization of uremic "middle molecular" fractions by gas chromatography, mass spectrometry, isotachophoresis, and liquid chromatography. Clin Chem. 1982; 28:45-49.
44. Henderson LW, Miller ME, Hamilton RW, Norman ME. Hemodialysis leukopenia and polymorph random mobility-a possible correlation. J Lab Clin Med. 1975; 85:191-197.
45. Kjellstrand P, Jacobson SH, Skroder R, et al. Leukocyte overshoot: A new sign of bioincompatibility in fast hemodialysis. ASAIO Trans. 1990; 36:M314-M316.
46. Skroeder R, Kjellstrand P, Holmquist SH, Kjellstrand C, Jacobson S. Individual differences in biocompatibility responses to hemodialysis. Int J Artif Organs. 1994; 17:521-530.
47. Skröder R, Jacobson SH, Lins LE, Kjellstrand CM. Bio-compatibility of dialysis membranes is of no importance for objective or subjective symptoms during or after hemodialysis. Trans ASAIO. 1990; 36: 637-639.
48. Bergamo Collaborative Dialysis Study Group. Acute intradialytic well-being: Results of a clinical trial comparing polysulfone with cuprophan. Kidney Int. 1991; 40:714-719.
49. Eknoyan G, Beck GJ, Cheung AK, et al. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347:2010-2019.
50. Martin K, Laydet E, Canaud B. Design and technical adjustment of a water treatment system: 15 years of experience. Adv Ren Replace Ther. 2003; 10:122-132.
51. Szathmary S, Hegyi E, Amoureux MC, et al. Characterization of the DialGuard device for endotoxin removal in hemodialysis. Blood Purif. 2004; 22:409-415.
52. Kleophas W, Haastert B, Backus G, Hilgers P, Westhoff A, van Endert G. Long-term experience with an ultrapure individual dialysis fluid with a batch type machine. Nephrol Dial Transplant. 1998; 13:3118-3125.
53. Fassbinder W. Experience with the GENIUS hemodialysis system. Kidney Blood Press Res. 2003; 26:96-99.
54. Twardowski ZJ. PHD: The technological solution for daily hemodialysis? Nephrol Dial Transplant. 2003; 18:19-23.
55. Kjellstrand CM, Blagg CR, Twardowski Z, Bower J. Approaches to quotidian dialysis: The Aksys personal hemodialysis system. Semin Dial. 2004; 17:151-153.
56. Kenley R. Efficacy of heat disinfection with the Aksys personal hemodialysis system. Home Hemodial Int. 1997; 1:36-40.
57. Blagg C, Twardowski Z, Bower J, Kjellstrand C. Cardiovascular instability and dialysate purity [abstract]. ASAIO J. 2003; 49:190.
58. Blagg CR, Bower JD, Twardowski ZJ, Kjellstrand CM. Well-being during dialysis with biocompatible high flux, high efficiency dialyzers and ultra-pure dialysate [abstract]. J Am Soc Nephrol. 2001; 2:371A.
59. Kjellstrand C, Twardowski ZJ, Bower J, Blagg CR. Hot water reuse of dialysis filters gives smoother dialysis than single use or chemical reuse. J Am Soc Nephrol. 2003; 14: 502A.
60. Kjellstrand C, Blagg CR, Twardowski ZJ, Bower J. Cardiovascular stability during dialysis - relative influence of dialysis purity, clearance and ultrafiltration speed [abstract]. ASAIO J. 2004; 50:177.
61. Kjellstrand CM, Blagg CR, Young B, Bower J, Twardowski ZJ. 106 patient-years experience with the Aksys PHD system for quotidian home hemodialysis [abstract]. Hemodial Int. 2005; 9:80-81.
62. Ouseph R, Jacobs AA, Ward RA. The use of ultrafiltered dialysate reduces inflammation in hemodialysis patients. J Am Soc Nephrol. 2003; 14:30A.
63. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 2000; 15:1207-1211.
64. Bonforte G, Grillo P, Zerbi S, Surian M. Improvement of anemia in hemodialysis patients treated by hemodiafiltration with high-volume on-line-prepared substitution fluid. Blood Purif. 2002; 20:357-363.
65. Schiffl H, Lang SM, Stratakis D, Fischer R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant. 2001; 16:1863-1869.
66. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant. 2002; 17:1814-1818.
67. Baz M, Durand C, Ragon A, et al. Using ultrapure water in hemodialysis delays carpal tunnel syndrome. Int J Artif Organ. 1991; 14:681-685.
68. 2-microglobulin associated amyloidosis: A vanishing complication of long-term hemodialysis? Kidney Int. 1997; 52:1077-1083.
69. Lonnemann G, Koch KM. Beta(2)-microglobulin amyloidosis: Effects of ultrapure dialysate and type of dialyzer membrane. J Am Soc Nephrol. 2002; 13(Suppl 1):S72-S77.
70. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55:648-658.
71. Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int. 2002; 80 (Suppl): S99-S102.
72. Lederer SR, Schiffl H. Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by reducing continuous microinflammation. Nephron. 2002; 91:452-455.